Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Looking for participantsNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)Looking for participantsNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 20
Early research (Phase 1)Ended earlyNCT03490838
What this trial is testing

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Advanced Accelerator Applications 27
Large-scale testing (Phase 3)Study completedNCT03511664
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Endocyte 861
Testing effectiveness (Phase 2)Looking for participantsNCT06972628
What this trial is testing

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Who this might be right for
Metastatic Castration-Resistant Prostate CancerProstate Cancer Patients With Bone MetastasisProstate Cancer (CRPC)+2 more
Ebrahim S Delpassand 30
Not applicableTemporarily Not AvailableNCT06033001
What this trial is testing

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castration-Resistant Prostatic Cancer
Lantheus Medical Imaging
Large-scale testing (Phase 3)Looking for participantsNCT07311694
What this trial is testing

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 370